Global Colorectal Cancer Drugs Market to Reach USD 12.79 Billion by 2028 with Notable CAGR of 4.57%
28 mars 2024 11h19 HE
|
Research and Markets
Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Global Colorectal Cancer Drugs Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis."...
Capecitabine Global Market Report 2024
06 mars 2024 04h09 HE
|
Research and Markets
Dublin, March 06, 2024 (GLOBE NEWSWIRE) -- The "Capecitabine Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The capecitabine market size is expected to see...
Capecitabine Market Research Reveals Significant Growth in Oncology Treatment Sector
09 janv. 2024 18h48 HE
|
Research and Markets
Dublin, Jan. 09, 2024 (GLOBE NEWSWIRE) -- The "Capecitabine Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The latest market research on capecitabine, a...
Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
19 déc. 2023 09h00 HE
|
Processa Pharmaceuticals, Inc.
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU Interim analysis of the NGC-Cap Phase 1b data shows improved...
Cholangiocarcinoma Market revenue to hit USD 1.3 Billion by 2036, says Research Nester
07 déc. 2023 06h30 HE
|
Research Nester
New York , Dec. 07, 2023 (GLOBE NEWSWIRE) -- The global cholangiocarcinoma market size is projected to grow at a CAGR of over 4% from 2024 to 2036. The market is expected to garner a revenue of USD...
Capecitabine Market to Hit US$ 1,558.74 Million By 2030 | Updated Analysis
29 août 2023 11h00 HE
|
CONSEGIC BUSINESS INTELLIGENCE PRIVATE LIMITED
New York, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The global Capecitabine Market is expected to witness significant growth at a remarkable CAGR of 5.5% during the forecast period of 2023-2030. The factors...
Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative
18 mai 2023 08h00 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, May 18, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”) today announces it has received guidance from the U.S. Food and Drug...
Investigation Report on China's Capecitabine Market 2021-2025 Featuring Shanghai Roche Pharma, Jiangsu Hengrui Medicine , Qilu Pharma, Chia Tai Tianqing Pharma Group & Hoffmann-La Roche
31 déc. 2021 05h48 HE
|
Research and Markets
Dublin, Dec. 31, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Capecitabine Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. Capecitabine is a pyrimidine...
ASLAN Pharmaceuticals Presents Late-Breaking Data From Phase 2 Study in China Testing Varlitinib in Second Line Biliary Tract Cancer at CSCO
19 sept. 2019 03h50 HE
|
ASLAN PHARMACEUTICALS LIMITED
- Biliary tract cancer (BTC) patients treated with varlitinib plus capecitabine in second line achieved a response rate of 11% including two complete responses, median PFS of 2.7 months and OS of 5.8...